Skip to main content
Keeping you afloat amidst the rising sea of regulations

45 Hospital and Health Care Executives Outline the Hospital of the Future

Health Care partner Tom Jeffry, and 44 other health care executives, spoke to Becker’s Hospital Review about the key trends disrupting the traditional hospital and how institutions can prepare for the future. “Looking towards the future, hospitals will devote more space and technology to accommodate advances in diagnostics and surgical procedures. New technologies will continue to reduce inpatient admissions as well as the number of days inpatients remain in the hospital.

South Carolina Hospital Settles With OIG Over Alleged EMTALA Violations Involving Psychiatric Emergencies

AnMed Health, a hospital located in South Carolina, recently agreed to pay almost $1.3 million dollars and enter into a settlement agreement with the HHS Office of Inspector General (OIG) to resolve allegations that it violated the Emergency Medical Treat

Bitcoin for Care: Healthcare Hopping on the Blockchain

* The following alert was originally published in California Healthcare News (CHN). To read it on the CHN website, click here.

FDA Issues Draft Guidance For Product Identifier Requirements

Last week, the FDA released a draft guidance titled Product Identifier Requirements Under the Drug Supply Chain Security Act--Compliance Policy, with a 60-day comment period ending around September 3, 2017.

Will Opioid Manufacturers Become the Next Big Tobacco?

With the federal response to the opioid crisis still under development, state and local governments continue to file lawsuits against the pharmaceutical companies that manufacturer these products, accusing them of misleading doctors and consumers about the risks of addiction.

FDA Publishes Action Plan Designed to Address Generic Drug Competition Barriers

On June 21, the Food and Drug Administration announced a Drug Competition Action Plan in order to attempt to address ways that the agency's rules have been, in the agency's view, “gamed” to create obstacles that delay generic drug approvals to reduce generic competition.

It’s About Time: Medicare Providers, Suppliers, and CLIA Laboratories No Longer Required to Write Plan of Correction on Right Side of Form 2567

In a move that practically all Medicare providers, suppliers, and Clinical Laboratory Improvement Amendments laboratories will welcome, the Centers for Medicare & Medicaid Services has declared that Plans of Correction and Allegations of Compliance no longer must be input directly onto the Statement of Deficiencies form (also known as “Form 2567”).

OCR’s Quick-Response Checklist for Cyber Attacks Useful for Responding to Petya Ransomware Blitz

Earlier this year, ransomware known as Wannacry crippled Britain’s National Health Service and spread across the globe affecting many other organizations, large and small. Now, many organizations are grappling with a new onslaught caused by similar ransomware dubbed Petya.

Sweeping Nevada Law to Impact Manufacturers, PBMs, Pharma Sales Representatives, and Nonprofit Organizations

Nevada is the latest state in the Union to adopt some form of a drug pricing transparency law, after Nevada Governor Brian Sandoval signed Senate Bill No. 539 into law on June 15, 2017. The breadth and scope of this particular bill is unlike any other transparency bill that we have seen to date, and has the potential to impact not only the manufacturers of the narrow class of drugs the bill focuses on, but all manufacturers with sales forces in Nevada, as well as non-profit patient assistance programs.  

Washington’s Best Kept Secret Revealed: What’s in the Senate Health Care Bill

After weeks of closed-door meetings about the content of the Senate’s health care bill, Senate Republicans released a “discussion draft” of their legislation on Thursday. The bill, titled the “Better Care Reconciliation Act of 2017” or BCRA, is the Senate’s response to the bill passed by the House of Representatives in May.